GeneDx Holdings Corp.: management transactions · United States · SEC (Form 4)

About GeneDx Holdings Corp.

GeneDx Holdings Corp. is a U.S.-based company listed on Nasdaq (United States) that specializes in clinical genomics and rare-disease diagnostics. The company’s core mission is to turn complex genetic data into actionable medical answers for patients, families, and clinicians. Founded in 2000 and headquartered in Stamford, Connecticut, GeneDx has built a strong position in exome and whole-genome sequencing, with a particular focus on pediatrics, neonatology, pediatric neurology, and neurodevelopmental disorders. GeneDx’s business model is centered on genetic diagnostic testing, especially exome sequencing, whole genome sequencing, and rapid genome sequencing for critically ill patients. The company emphasizes its proprietary GeneDx Infinity™ dataset, which it describes as one of the largest rare-disease data assets in the field. That dataset supports variant interpretation, improves diagnostic yield, and reinforces the company’s competitive differentiation. In a market where many providers offer broad laboratory testing, GeneDx stands out as a specialist in high-complexity genomic medicine, combining clinical expertise, data scale, and software-enabled interpretation. From a competitive perspective, GeneDx positions itself as more than a testing vendor. It aims to be a clinical partner embedded in care pathways. The company has expanded integrations with hospital systems and electronic health record workflows, making it easier for clinicians to order tests and review results in routine practice. This matters because rare-disease diagnosis often involves a long and costly diagnostic odyssey, and GeneDx markets its platform as a way to shorten the time to an answer and improve downstream care decisions. Its key offerings include ExomeDx™, GenomeDx™, rapid sequencing solutions for NICU and PICU settings, and telehealth pathways that help families access genetic counseling and testing more easily. Geographically, the business is primarily U.S.-focused, with the United States being its main commercial market. GeneDx is also expanding payer and state Medicaid coverage, which is strategically important because reimbursement is a major driver of adoption in clinical genomics. Recent developments have been notable. In 2025, GeneDx highlighted expansion of genome coverage through California Medicaid (Medi-Cal), new partnerships around genomic newborn screening, a telehealth pathway to broaden access to exome testing, and FDA Breakthrough Device Designation for ExomeDx and GenomeDx. The company also continued to invest in AI- and data-driven interpretation capabilities, reinforcing its leadership narrative in rare-disease genomics. For French, Belgian, and Swiss investors, GeneDx is best viewed as a healthcare growth story tied to structural adoption of genomic diagnostics, clinical standard-of-care expansion, and reimbursement normalization in the U.S. market.